April 23, 2015

ARAVIS sells two German wind farms

Aravis Energy I LP, a Swiss renewable energy fund advised by Aravis, successfully completed the sale of two companies comprising two German wind farms to a Swiss power supplier. “We have once again been able to successfully exit investments, which further strengthens our track record of delivering returns to investors. This proves our agility and high-quality skills of implementing attractive investment projects in accordance with the investment strategy.’’, commented Oliver Thalmann, Managing Partner of Aravis. The German wind farms are located in Rhineland-Palatinate respectively Brandenburg. Both wind farms benefit from attractive long-term feed-in tariffs. These tariffs do not correlate with other commodity market prices such as those for oil and gas, thereby offering an efficient diversification effect to investors.
PDF Download

read more »

April 23, 2015

Biotie provides update on tozadenant Phase 3 program

Biotie has further refined its plans for the design and conduct of Phase 3 trials in Parkinson's disease (PD) patients experiencing levodopa related end-of-dose 'wearing-off' (motor fluctuations). The phase 3 program will consist of a double- blind trial with an open-label extension and, providing this demonstrates safety and efficacy, will be followed by a separate open-label trial to generate further clinical safety data.
PDF Download

read more »

April 23, 2015

Evolva completes transfer of EV-035 to Emergent BioSolutions, triggering a USD 4 million payment

Evolva (SIX: EVE) today announces the US government’s approval of the transfer (“novation”) of the GC-072 contract to Emergent BioSolutions Inc. (NYSE: EBS). This triggers a payment of USD 4 million to Evolva, following an initial upfront payment of USD 1.5 million in December 2014. This does not change the revenue guidance for 2015.
PDF Download - English Version
PDF Download - German Version

read more »

April 15, 2015

Bilan, 15.04.2015 - L'etoile montante des medtech suisses

SYMETIS DOIT MAINTENANT CHANGER D'ECHELLE. CELA PASSE PAR SON RACHAT OU PAR UNE INTRODUCTION EN BOURSE

Apres une vague d'acquisitions , le  secteur  abesoin  de nouvelles  locomotives helvetiques.   En pleine  croissance, l'entreprise vaudoise  Symetis est une bonne  candidate.
PDF Download

read more »

March 31, 2015

Biotie announces start of patient enrolment into Phase 2a clinical study with BTT1023 in primary sclerosing cholangitis

Biotie Therapies Corp ("Biotie") announces the start of patient enrolment into the Phase 2a clinical study evaluating BTT1023, Biotie's fully human monoclonal antibody targeting Vascular Adhesion Protein-1, in primary sclerosing cholangitis (PSC). PSC is a progressive immune mediated biliary disease characterised by bile duct inflammation and fibrosis, and accompanying hepatic fibrosis, that frequently results in the need for liver transplantation. The study is being funded through the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership*.
PDF Download

read more »

March 26, 2015

Evolva and Valent BioSciences to co-develop agricultural bioactives

Evolva (SIX: EVE) and Valent BioSciences Corporation (VBC), a subsidiary of Tokyo-based Sumitomo Chemical Company, have signed an exclusive agreement to co-develop and commercialise a class of high-value active ingredients for use as next-generation agricultural bioactives. For competitive reasons, the ingredients are not being identified at this time.
PDF Download - English Version
PDF Download - German Version

read more »

March 10, 2015

Mallinckrodt to acquire Ikaria in $2.3 bln deal. Early investor Aravis Exits along side with PE Madison Dearborn

Ikaria is being sold for $2.3 billion to global biopharmaceutical company Mallinckrodt. In 2005 Aravis, through its Biotech venture I fund, had joined the initial Series A financing of Ikaria Inc, together with 5am, Venrock and Arch. Over time through various innovative M&A and financing steps the company has grown into a highly profitable specialty company. The purchase by Mallinckrodt follows last years’ partial sale to Madison Dearborne and the listing of Ikaria’s spin out Bellorophon (BLPH; NASDAQ).
PDF Download

read more »

March 10, 2015

Ajinomoto project moves into the next phase triggering a milestone payment to Evolva

Evolva (SIX: EVE) today announces that Ajinomoto Co. Inc., Japan, has confirmed that Evolva has completed the first R&D phase in their collaboration and that the collaboration is moving into its next phase. The ultimate objective of the collaboration is the joint development of novel fermentation production routes for a natural functional ingredient for application in Personal Care. Evolva has developed an innovative process that allows Ajinomoto to manufacture the target ingredient. In recognition of the progress and several new findings, Ajinomoto will make a milestone payment to Evolva.
PDF Download - English Version
PDF Download - German Version

read more »

February 27, 2015

Biotie Financial Statement Release 2014

Biotie Financial Statement Release 2014 - This is a summary of the financial statement report 2014 published today.

Company Highlights
October - December 2014 :

- Preparations to advance tozadenant into Phase 3 development in Parkinson's disease as part of Biotie's proprietary portfolio continued during the quarter. The Phase 3 program is expected to start recruiting patients in the middle of 2015.

- Biotie advanced SYN120, a 5-HT6 / 5-HT2a antagonist, into Phase 2 development. The SYNAPSE study, a Phase 2a clinical study in patients with Parkinson's disease dementia, started in December 2014. The study is largely funded by The Michael J. Fox Foundation (MJFF).

- Biotie's partner H. Lundbeck A/S (Lundbeck) continued the rollout of Selincro in Europe and it has now been introduced in 26 European markets. Favorable reimbursement decisions have been issued in a number of European markets, including France, Spain and the United Kingdom, where NICE issued its final positive guidance in November 2014.

- Annual impairment review of intangible assets and goodwill resulted in a non-cash impairment charge of EUR 27.6 million in respect of nepicastat and SYN120.

- Biotie's revenue in Q4 2014 was EUR 1.9 million (EUR 5.8 million) and the financial result was a net loss of EUR 32.4 million (net profit of EUR 1.7 million).

- Biotie ended 2014 with liquid assets of EUR 32.4 million (EUR 35.9 million, 30 September 2014). Operating cash flow for the full year was a net outflow of EUR 14.1 million (net inflow of EUR 10.6 million).

PDF Download

read more »

February 16, 2015

Aravis to present at the Innovationsforum Energie in Zurich on the 20th of March

Aravis has been invited to speak at the 5th Innovationsforum Energie in Zurich on 20th March 2015. Besides sharing practical insights from Aravis experiences in Investment in the energy sector, the following pertinent issues will be addressed:
- Analysing the market to ascertain what is the appetite of investors for European Infrastructure;
- How do Financial Investors view investments in the Energy sector today;
- What are some possible collaborations models between utilities and financial investors when financing energy infrastructure projects?

read more »

February 13, 2015

Bellerophon Therapeutics Announces Pricing of Its Initial Public Offering

Bellerophon Therapeutics announced today the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $12.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Bellerophon. In addition, Bellerophon has granted the underwriters an option to purchase up to 750,000 additional shares of common stock at the public offering price, less the underwriting discount.  Bellerophon's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the ticker symbol "BLPH" on February 13, 2015.  The offering is expected to close on February 19, 2015, subject to customary closing conditions.
PDF Download

read more »

February 12, 2015

MerLion announces FDA approval of finafloxacin otic suspension - First novel drug from a Singapore company to achieve FDA approval

MerLion Pharmaceuticals (MerLion), a biopharmaceutical company headquartered in Singapore with clinical development operations in Berlin, Germany, today announced that an otic suspension of finafloxacin has been approved by the FDA to treat acute otitis externa, commonly known as “swimmer’s ear”, caused by Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin was licensed by MerLion to a major North American partner in 2010 for use in North America for otic (ear) infections.
PDF Download

read more »

February 09, 2015

Evolva provides financial and project update

Evolva (SIX: EVE) today provides a financial and project update.According to the provisional, unaudited financials, revenues in 2014 slightly exceeded CHF 10 million (in line with guidance), whilst the year-end cash position of CHF 60.7 million was higher than the CHF 50 million projected in November 2014.
PDF Download - English Version
PDF Download - German Version
 

read more »

January 29, 2015

Aravis sponsors the Wind Risk Management and Mitigation Forum in London on the 4th and 5th of February

Aravis is proud to sponsor the Wind Risk Management and Mitigation Forum taking place in London on the 4th and 5th of February. The conference is organised by Wind Power Monthly, which is widely regarded as the most prestigious magazine in the wind energy sector. In addition, on the second day Aravis will be presenting the topic “Assessing The Impact Of Weather Risk On Cash Flow”. We are excited about the event and are looking forward to meeting you at the conference.

read more »

January 19, 2015

Evolva and Cargill to collaborate on second family of ingredients

Evolva Holding SA (“Evolva”; SIX: EVE) and Cargill have signed an agreement to co-develop a sustainable, customisable, and cost-effective fermentation production process for a second family of high-value food and beverage ingredients.
PDF Download - English Version
PDF Download - German Version

read more »

January 08, 2015

Evolva and L’Oréal reach first milestone in innovative cosmetics ingredient project

Evolva Holding SA (SIX: EVE) today announces the successful completion of the first part of its R&D collaboration with L’Oréal. The parties have agreed to move into the next phase of the multi-year programme.
PDF Download - English Version
PDF Download - German Version

read more »